Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in American men and women [1]. It is estimated that CRC-related deaths in the United States will exceed 51,000 in 2019 [1]. Five-year survival for patients diagnosed with localized CRC is 90%; however, only 39% of patients with CRC are diagnosed at that stage [1]. Tumor location is also an important factor, as survival rates are lower for patients with tumors in the proximal colon versus the distal colon and rectum, based on a meta-analysis of 66 studies (pooled hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.79–0.84) [2].

Colonoscopy is considered the “gold standard” among CRC screening tests and is both diagnostic and therapeutic [3–5]. A critical component of a successful colonoscopy is adequate bowel preparation. It has been noted that the CRC risk reduc-
tion associated with screening colonoscopy generally has been lower for proximal cancers compared with distal cancers [6–11]. One of the hypotheses for this observation is that flat and serrated lesions, which are more common in the proximal colon, may be missed due to suboptimal bowel preparation. This narrative review discusses data on the impact of bowel preparation on colonoscopy quality and describes characteristics of currently available bowel preparation options.

Importance of colorectal cancer screening

Prennalignant lesions that progress to CRC include conventional adenomas and sessile serrated polyps (SSPs) [12–14]. Because early-stage CRC is typically asymptomatic, screening is required to identify premalignant and malignant colorectal neoplasia, ideally at an early, curable stage [13]. Evidence from multiple studies supports the efficacy of colonoscopy for decreasing CRC incidence, as well as improving the prognosis and reducing mortality rates [4–8, 10, 11, 15, 16].

In the United States, the CRC-related mortality rate declined by more than 50% from 1970 to 2016 [1], mostly as a result of increased CRC screening and polyp removal [12]. Whereas changes before 2000 are attributable to reductions in risk factors and the increased use of screening, more recent declines are primarily attributable to the increased use of colonoscopy [17, 18]. Guidelines from the US Preventive Services Task Force [19] and the US Multi-Society Task Force of Colorectal Cancer (MSTF) [20] recommend that asymptomatic, average-risk individuals initiate routine screening at 50 years of age. However, the American Society for Gastrointestinal Endoscopy and the American College of Gastroenterology suggest initiating CRC screening at 45 years for African Americans [20, 21]. More recently, the 2018 American Cancer Society guidelines provided a qualified recommendation to initiate CRC screening at age 45 years in all individuals [22], based on data showing the rising incidence of CRC among adults aged <50 years [23–25].

In 2012, 27.7% of individuals between ages 50 and 75 years who were eligible for routine CRC screening in the United States had never undergone screening [26]. One retrospective community-based study showed that a significantly lower percentage of patients scheduled for screening colonoscopy attended the procedure, compared with patients scheduled for surveillance or diagnostic colonoscopy (45.5% vs 65.3%, respectively; P<0.0001) [27]. Results of a survey of individuals between ages 50 and 75 years (68% of whom had previously undergone CRC screening) showed that the most common patient barriers to CRC screening included fear (10.1%), unpleasantness of the bowel preparation (7.9%), lack of awareness of or knowledge regarding CRC screening (7.9%), pain (7.6%), and economic limitations (6.0%) [28].

Importance of adenoma detection rates

The adenoma detection rate (ADR) is the most important quality benchmark for screening colonoscopy [29]. For average-risk patients aged ≥50 years, it is defined as the percentage of screening colonoscopies performed by an endoscopist in which one or more adenomas are found [29, 30]. Prevalence of adenomas varies by patient age (higher in older patients) and sex (higher in men), with the minimum recommended ADR target of ≥30% in men and 20% in women [29, 31]. ADR is inversely associated with the incidence and mortality of postcolonoscopy or “interval” CRC [32, 33]. Interval CRC is cancer that occurs in an individual prior to the time interval recommended for the next CRC screening test. In one study, up to 9% of individuals with CRC had previous exposure to colonoscopy, often within the past 3 years [34].

During the last decade, large screening studies have confirmed that a higher ADR is significantly associated with a lower risk of CRC and mortality from the disease [32, 33, 35]. A 2010 study (>45,000 patients; median follow-up, 52.1 months) reported that the risk of interval CRC was inversely associated with ADR [32]. The HR for developing CRC for an ADR between 15% to 19.9% compared with an ADR of 20% of more was 12.5 (95% CI, 1.5–103.4; P=0.02) [32]. A landmark 2014 study evaluated >260,000 colonoscopies and demonstrated that endoscopists with ADRs in the highest quintile (>33.5%) had lower risks for patients developing interval CRC (HR=0.52; 95% CI, 0.39–0.69), including advanced-stage interval CRC (HR=0.43; 95% CI, 0.29–0.64) and fatal interval CRC (HR=0.38; 95% CI, 0.22–0.65), compared with endoscopists who had ADRs in the lowest quintile (<19.1%) [33]. For every increase of 1% in ADR, the risk of interval CRC was reduced by 3%, and the risk of fatal CRC was reduced by 5% [33]. Similarly, an analysis that used community-based healthcare system data noted that for every 5% increase in ADR, the lifetime incidences of CRC risk and mortality were 11.4% and 12.8% lower, respectively [35].

Quality of bowel preparation

Given the important relationship between ADR and CRC risk, effective bowel preparation before colonoscopy is essential for optimizing the detection of colorectal neoplasia, and adequate bowel preparation is an important quality metric for colonoscopy (Fig. 1) [29, 30].

For this narrative review, a search of the PubMed database was conducted to identify English-language publications available through June 2019, using the following keywords: “colon cancer,” “colorectal cancer,” “colorectal carcinoma,” “colonoscopy,” “colorectal cancer screening,” “bowel preparation,” “quality,” “bowel preparation scales,” “adenoma detection,” “polyethylene glycol,” “PEG,” “sodium phosphate,” “sodium sulfate,” “PEG-3350,” “PEG-3550,” “magnesium citrate,” “polyethylene glycol plus ascorbate,” “PEG plus ascorbate,” “NER1006,” “sodium picosulfate,” “efficacy,” “safety,” “adverse events,” “tolerability,” and “preference.” Article bibliographies were reviewed to identify additional publications.

Bowel preparation quality scales

Several scales have been developed to assess the quality of bowel preparation (Table 1 and Table 2) in the various segments of the colon (Fig. 2) [36–42]. The Aronchick Scale – the first scale introduced for evaluating bowel preparation quality – uses an overall rating for the entire colon on a five-point scale from “inadequate” to “excellent” [37]. The Harefield Cleansing Scale involves the analysis of five colon segments using a five-point segmental scale (range, 0 [irremovable, heavy, hard
stools] to 4 [empty and clean]). Overall cleansing success is assessed using a four-grade system (i.e., A [high-quality] to D [failure], with grade A requiring all five segments to have scores of 3 or 4) [41]. Although the Aronchick Scale is widely used, it has not been formally validated or shown to correlate with clinical outcomes. The Harefield Cleansing Scale is validated; an increasing body of clinical outcomes evidence indicates that it is particularly useful for rigorous clinical studies.

The Ottawa Bowel Preparation Scale was designed as a research tool for evaluating differences between bowel preparations and regimens [36] and consists of ratings for three colon segments (i.e., right, mid, recto-sigmoid) on a five-point scale and an overall rating of the amount of fluid in the colon [38, 39].

The Boston Bowel Preparation Scale consists of ratings for three colon segments on a four-point scale [40, 43]. A systematic review found the Boston Bowel Preparation Scale to be the most thoroughly validated and clinically relevant scale [36]. The Chicago Bowel Preparation Scale, introduced in 2013, was developed most recently. It rates the cleanliness of the right, transverse, and left colon segments on a scale from 0 to 12, for a total cleanliness score of 0 (very poor) to 36 (outstanding) [42]. Scoring is performed after washing or suctioning the colonic mucosa. Further, the total fluid volume in the colon is precisely quantified and scored [42]. The Chicago Bowel Preparation Scale is not as widely used or suitable for routine practice as is the Boston Bowel Preparation Scale [36].

Clinical importance of adequate bowel preparation

Studies have reported that bowel preparation is inadequate in 15% to 35% of colonoscopies, with rates varying across medical settings and patient populations [44–50]. Inadequate bowel preparation negatively impacts the ADR and other indicators of colonoscopy quality (e.g., cecal intubation rates), lengthens procedure times (e.g., increased time washing and suctioning debris, prolonged withdrawal time), and results in shorter surveillance intervals and increased costs [44, 46, 49, 51–60]. A pooled analysis of eight prospective studies (n = 9167) found that metachronous CRC was diagnosed in 0.6% of patients

Table 1 Bowel preparation grading scales assessing quality across the length of the colon [36–42]

<table>
<thead>
<tr>
<th>Points</th>
<th>Aronchick Scale</th>
<th>Chicago Bowel Preparation Scale</th>
<th>Ottawa Bowel Preparation Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>–</td>
<td>Little fluid (≤ 50 cc)</td>
<td>Small amount of fluid</td>
</tr>
<tr>
<td>1</td>
<td>Excellent: small volume of clear liquid or &gt;95 % of surface seen</td>
<td>Minimal amount of fluid (51–150 cc)</td>
<td>Moderate amount of fluid</td>
</tr>
<tr>
<td>2</td>
<td>Good: large volume of clear liquid covering 5 % to 25 % of the surface but greater than 90 % of surface seen</td>
<td>Moderate amount of fluid (151–300 cc)</td>
<td>Large amount of fluid</td>
</tr>
<tr>
<td>3</td>
<td>Fair: some semi-solid stool that could be suctioned or washed away, but &gt;90 % of surface seen</td>
<td>Large amount of fluid (&gt; 300 cc)</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>Poor: semi-solid stool that could not be suctioned or washed away, and &lt;90 % of surface seen</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>Inadequate: repeat preparation needed</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total score ranges</td>
<td>1 (excellent) to 5 (inadequate)</td>
<td>0 (little fluid) to 3 (large amount of fluid)</td>
<td>0 (small amount of fluid) to 2 (large amount of fluid)</td>
</tr>
</tbody>
</table>

who had a preceding normal colonoscopy, yielding an interval CRC incidence rate of 1.7 per 1000 person-years of follow-up; lesions missed at screening were predicted to account for 51.7% of interval CRCs [61]. Compared with screen-detected cancer, interval CRCs are more likely to occur in the proximal colon [62–65]. A meta-analysis of 12 studies calculated that in-terval CRC cases, compared with detected CRC cases, were 2.4 times more likely to occur in the proximal colon versus the distal colon [66]. In a pooled analysis of the eight studies noted above [61], 29 (50.0%) of the 58 interval CRCs were proximal to the splenic flexure and significantly more likely to be missed (as indicated by occurrence of CRC within 3 years of a prior co-

<table>
<thead>
<tr>
<th>Points</th>
<th>Boston Bowel Preparation Scale</th>
<th>Chicago Bowel Preparation Scale</th>
<th>Harefield Cleansing Scale</th>
<th>Ottawa Bowel Preparation Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Unprepared colon segment with stool that cannot be cleared</td>
<td>Unprepared colon segment with stool that cannot be cleared (&gt;15% of mucosa not seen)</td>
<td>Unremovable, heavy, hard stools</td>
<td>Excellent: mucosal detail clearly visible</td>
</tr>
</tbody>
</table>
| 1      | Portion of mucosa in segment seen after cleaning, but other areas not seen because of retained material | | Semisolid, only partially remova-
| | | | ble stools | Good: minimal turbid fluid in segment |
| 2      | Minor residual material after cleaning, but mucosa of segment generally well seen | | Brown liquid/fully removab-
| | | | le semi-solid stools | Fair: necessary to suction liquid to adequately view segment |
| 3      | Entire mucosa of segment well seen after cleaning | | Clear liquid | Poor: necessary to wash and suc-
| | | | tion to obtain a reasonable view | |
| 4      | | | Empty and clean | Inadequate: solid stool not cleared with washing and suctioning |
| 5      | | | Some of mucosa in segment seen after cleaning, but ≤15% of mucosa not seen due to retained material | |
| 10     | | | Minor residual material after cleaning, but mucosa of segment generally well seen | |
| 11     | | | Entire mucosa of segment well seen after washing | |
| 12     | | | Entire mucosa of segment well seen without washing | |
| Segments scored | Right colon; transverse colon, including hepatic and splenic flexures; left colon | Right colon; transverse colon; left colon | Cecum and ascending colon; transverse colon; descending colon; sigmoid colon; rectum | Right colon (cecum and ascending colon); mid colon (transverse and descending colon); rectosigmoid colon |
| Scoring ranges | Each segment score: 0 to 3 Total score: 0 (unprepared colon) to 9 (clean colon) | Each segment score: 0 to 12 Total score: 0 (very poor) to 36 (outstanding) | Successful: A: all segments with score 3 or 4 B: ≥1 segment with score 2 Unsuccessful: C: ≥1 segment with score 1 D: ≥1 segment with score 0 | Each segment score: 0 to 4 Whole colon fluid score: 0 to 2 Total score: 0 (perfect) to 14 (completely unprepared colon) |


Guidelines from the MSTF recommend repeat colonoscopy within 1 year for patients with inadequate bowel preparation [67]. Adequate bowel preparation is important for high-quality screening colonoscopy, for maximizing the efficacy of the exam in the proximal colon [68], and also for identifying lesions that are more difficult to detect [69]. These factors are likely inter-related, because the predominance of SSPs and other flat and depressed lesions is greater in the proximal colon [68, 69].
Quality of bowel preparation has been associated with ADRs in multiple studies [46, 49, 50, 70–74]. A retrospective study of screening colonoscopies at an academic medical center reported a per-adenoma miss rate (defined as the number of adenomas found on repeat examination divided by the sum of the number of adenomas identified on initial and repeat examination) of 47.9% in 373 patients with inadequate bowel preparation [72]. Similarly, a retrospective study at a hospital-based endoscopy unit found a miss rate of 41.9% for all adenomas and 27.5% for advanced adenomas in patients with suboptimal (poor or fair) bowel preparation [46]. A meta-analysis showed that, compared with low-quality bowel preparations, ADRs were significantly greater with intermediate (odds ratio [OR], 1.4; 95% CI, 1.1–1.8) and high-quality bowel preparations (OR, 1.4; 95% CI, 1.2–1.6) [70]. Based on the relationship between inadequate bowel preparation and decreased ADR, it is plausible that improving bowel preparation quality might reduce risk of interval CRC.

Inadequate bowel preparation is also associated with incomplete screening colonoscopy [49]. Further, excellent bowel preparation quality was significantly associated with shorter cecal intubation time (5.7 minutes) versus that for good (6.9 minutes), fair (7.6 minutes), or poor bowel preparation quality (7.4 minutes; P<0.001 for comparisons of different bowel preparation qualities) [75].

Factors that affect bowel preparation quality
A number of product- and patient-related factors may impact the quality of bowel preparation (Table 3) [67, 76–84], including comorbid conditions and the use of certain pharmacologic agents [85, 86]. A retrospective single-center study (n = 404) of patients undergoing a screening or diagnostic colonoscopy reported that those with diabetes had a significantly increased risk of poor-quality bowel preparation compared with those without diabetes (OR, 3.5; 95% CI, 1.4–8.7) [86]. This study also found that patients with fewer than three bowel movements per week were at significantly greater risk of poor-quality bowel preparation compared with patients with 3 to 14 bowel movements per week (OR, 5.2; 95% CI, 1.8–15.2) [86].

Inadequate bowel preparation is associated with incomplete screening colonoscopy [49]. Further, excellent bowel preparation quality was significantly associated with shorter cecal intubation time (5.7 minutes) versus that for good (6.9 minutes), fair (7.6 minutes), or poor bowel preparation quality (7.4 minutes; P<0.001 for comparisons of different bowel preparation qualities) [75].

### Table 3 Factors that can improve bowel preparation quality [67, 76–84].

<table>
<thead>
<tr>
<th>Product-related factors</th>
<th>Patient-related factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tolerability</strong></td>
<td><strong>Adherence to instructions</strong></td>
</tr>
<tr>
<td>Low preparation volume</td>
<td>Patient education</td>
</tr>
<tr>
<td>Adequate palatability</td>
<td>Health literacy</td>
</tr>
<tr>
<td><strong>Dosing regimen</strong></td>
<td>Motivation</td>
</tr>
<tr>
<td>Split-dosing (2-day or same day of colonoscopy)</td>
<td></td>
</tr>
<tr>
<td><strong>Timing of administration</strong></td>
<td></td>
</tr>
<tr>
<td>Final dose completed within 2 to 5 hours before the start of the procedure</td>
<td></td>
</tr>
</tbody>
</table>

Noncompliance to dosing instructions has been shown to be a strong predictor of suboptimal bowel preparation (OR, 6.7; 95% CI, 3.2–14.2) [87]. An analysis of average-risk patients who underwent routine screening colonoscopy showed that 86.7% of patients with poor bowel preparation had either failed to complete the preparation or failed to follow the written instructions on timing of preparation or dietary restrictions [48]. A meta-analysis of randomized studies reported that enhanced patient education was associated with greater dosing instruction adherence and higher-quality bowel preparation [76]. Several patient characteristics associated with inadequate bowel preparation (e.g., older age, lower education level, Medicaid insurance) [47, 88] may serve as proxies for lower health literacy, which highlights the importance of providing bowel preparation instructions that are easy to understand [78, 89], as well as clearly explaining to patients why it is important to complete the preparation as instructed.

Tolerability is strongly affected by characteristics of the bowel preparation product and the regimen for administration [90]. The requirement of a high volume of bowel preparation is identified by patients as a deterrent to participation in screening colonoscopies [91]. Low-volume and split-dose regimens are associated with improved tolerability [67], but adverse effects from low-volume bowel preparations, including dehydration, hyponatremia, and other fluid and electrolyte imbalance—

---

**Fig. 2 Colon anatomy.**

related hospitalizations, are more common than with high-volume preparations [92, 93]. Elderly patients or patients with impaired renal function should be monitored closely. Carbohydrate-electrolyte rehydration solutions (e.g., sports drinks) may be contraindicated in patients with diabetes, as well as in those with renal insufficiency, due to the risks of hyperglycemia and potassium overload, respectively [93].

Split-dosing, with at least 50% of the bowel preparation consumed on the day of the exam, is recognized as superior in both efficacy and tolerability compared with day-before dosing [67, 94]. A meta-analysis of five randomized trials reported that split-dosing of 4L polyethylene glycol (PEG), compared with day-before dosing, increased the number of adequate bowel preparations (OR 3.7; 95% CI, 2.8–4.9), patient willingness to repeat the preparation for a subsequent colonoscopy (OR 1.8; 95% CI, 1.1–2.9), and decreased incidence of nausea (OR 0.6; 95% CI, 0.4–0.8) [80]. Similarly, another meta-analysis reported that split-dosing increased the likelihood of an adequate bowel preparation (n = 32 studies; OR 2.5; 95% CI, 1.9–3.4) and patient willingness to repeat the preparation (n = 14 studies; OR 1.9; 95% CI, 1.0–3.5) [81]. The efficacy of same-day bowel preparation is supported by a meta-analysis of 15 randomized studies, which noted similar bowel preparation quality (relative risk [RR], 0.95; 95% CI, 0.90–1.00), ADR (RR, 0.97; 95% CI, 0.79–1.20), and patient willingness to repeat the process (RR, 1.14; 95% CI, 0.96–1.36) for same-day compared with split-dosing [83].

Regarding the timing between preparation and procedure (“runway time”), the likelihood of suboptimal preparation is increased for colonoscopies scheduled later in the day (OR, 1.9; 95% CI, 1.7–2.1) [47]; this situation may be a function of the longer time between the consumption of the bowel preparation and the procedure [95]. A prospective analysis of 378 consecutive outpatients from a single practice found that every hour a patient waited between the last preparation dose and the start of colonoscopy translated to a nearly 10% decline in the likelihood of receiving a good or excellent bowel preparation quality rating [95]. Thus, a shorter runway time may increase the chance of a good or excellent bowel preparation, which may, in turn, improve detection of colorectal neoplasia. A prospective observational study determined that 3 to 5 hours between the last dose of PEG and the start of the colonoscopy was the time frame that provided the best bowel preparation quality [84]. Guidelines strongly recommend split-dose bowel preparation, with same-day preparation as an alternative to 2-day split-dosing, particularly for patients who schedule an afternoon colonoscopy, with the last bowel preparation dose beginning 4 to 6 hours before and completed ≥2 hours before the procedure time [67].

**Bowel preparation regimens**

Selecting the optimal bowel preparation regimen is based on considerations of efficacy, safety, and tolerability, in conjunction with individual patient characteristics and preferences [90, 96]. Innovations in bowel preparation formulations were introduced to improve efficacy, tolerability, and safety [97]. Characteristics of the ideal bowel preparation include excellent efficacy for removing residual stool from the colon without affecting mucosal morphology or plasma fluid and electrolyte homeostasis, superior tolerability (in terms of palatability and adverse event [AE] profile), and safety, as well as being reasonably priced and simple to administer [97, 98]. Available bowel-cleansing agents differ by their mechanism of action and volume requirements (Table 4) [39, 90, 97, 99–110]. PEG agents are isotonic and act by retaining fluid within the lumen of the colon and small bowel [97]. In contrast, hypertonic reagents (e.g., sodium phosphate tablets) induce paracellular fluid shifts toward the lumen of the colon and small bowel [97].

Introduced in the early 1980s, the US Food and Drug Administration (FDA)–approved PEG electrolyte solution became the most commonly used agent for bowel preparation because of its favorable safety profile [108, 111]. However, 5% to 15% of patients do not ingest the recommended amount, primarily due to the large volume (4L) and poor palatability [39, 112]. High-volume PEG with a balanced electrolyte solution is recommended for patients with chronic constipation or previous inadequate bowel preparation and is needed for patients who cannot tolerate fluid or electrolyte shifts (e.g., patients with congestive heart failure or hepatic or renal failure) [109]. To address palatability issues, the potassium concentration was reduced and the sodium sulfate was removed to produce a 4-L sulfate-free PEG, which was considered more palatable and exhibited efficacy similar to the initial PEG preparations [39, 109]. However, tolerability remained suboptimal due to the large volume requirement. Thus, low-volume bowel preparation options – such as PEG plus ascorbate (2L and 1L), oral sodium sulfate, and sodium picosulfate plus magnesium oxide and anhydrous citric acid – have been developed and approved (Table 4).

An over-the-counter PEG product for the management of constipation (PEG-3550) has also been used for colonoscopy preparation [90, 107]. A 2013 survey of gastroenterologists revealed that more than one-third recommended PEG-3550 as a bowel preparation to patients, primarily in suburban settings [113]. PEG-3550 is not osmotically balanced, and electrolyte shifts, particularly hyponatremia, may occur, which could cause complications in patients with certain comorbidities [109]. Efficacy results with PEG-3550 have been mixed when compared with FDA-approved products [90, 109].

The FDA has approved two low-volume PEG products: a 2-L formulation approved in 2006 [101], and a 1L formulation (NER1006) approved in 2018 [102]. Both preparations are formulated with ascorbic acid and sodium ascorbate, which enhance the osmotic effect and may improve palatability [108]. In healthy individuals without constipation, low-volume PEG formulations provide bowel-cleansing effectiveness similar to that of 4L PEG [67]. In a 2014 meta-analysis of 11 randomized, controlled studies, the efficacy of 2L PEG plus ascorbate was comparable to that of 4L PEG, with improved tolerability and fewer adverse effects [114].

Unlike the 2-L PEG plus ascorbate, the bowel preparation NER1006, approved by the FDA in 2018, has a unique asymmetric dosing regimen. The first dose acts primarily as a debulking agent, and the second dose provides an osmotic washout. All of the ascorbate in NER1006 is administered with the second
<table>
<thead>
<tr>
<th>Product</th>
<th>Composition</th>
<th>Total volume</th>
<th>Indication/dosing</th>
<th>Most common AEs[^1]</th>
</tr>
</thead>
<tbody>
<tr>
<td>4L PEG</td>
<td>PEG-3350, sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride</td>
<td>4L (128 oz)</td>
<td>Bowel cleansing before colonoscopy and barium enema X-ray in adults</td>
<td>≤ 50% of patients: nausea, abdominal fullness, and bloating</td>
</tr>
<tr>
<td>4L PEG, sulfate-free</td>
<td>PEG-3350, sodium bicarbonate, sodium chloride, potassium chloride</td>
<td>4L (128 oz)</td>
<td>Bowel cleansing before colonoscopy in adults and pediatric patients ≥ 6 months of age</td>
<td>≤ 50% of patients: nausea, abdominal fullness, and bloating</td>
</tr>
<tr>
<td>2L PEG plus ascorbate</td>
<td>PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid</td>
<td>2L (64 oz) + 1L (32 oz) clear fluids</td>
<td>Bowel cleansing before colonoscopy in adults: split-dosing, 2-day or evening before (1-day)</td>
<td>≥ 2% of patients with 2-day dosing: malaise, nausea, abdominal pain, vomiting, upper abdominal pain, and dyspepsia</td>
</tr>
<tr>
<td>1L PEG plus ascorbate (NER1006)</td>
<td>PEG-3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, potassium chloride</td>
<td>1L (32 oz) + 1L (32 oz) clear fluids</td>
<td>Bowel cleansing before colonoscopy in adults: split dosing, 2-day or morning of (1-day)</td>
<td>&gt; 2% of patients: nausea, vomiting, dehydation, and abdominal pain/dishcomfort</td>
</tr>
<tr>
<td>Oral sodium sulfate</td>
<td>Sodium sulfate, potassium sulfate, magnesium sulfate</td>
<td>1L (32 oz) + 2L (64 oz) water</td>
<td>Bowel cleansing before colonoscopy in adults: split dosing, 2-day</td>
<td>≥ 2% of patients: overall discomfort, abdominal distension, abdominal pain, nausea, vomiting, and headache</td>
</tr>
<tr>
<td>Sodium picosulfate + magnesium oxide and anhydrous citric acid</td>
<td>Sodium picosulfate, magnesium oxide, citric acid</td>
<td>320 mL (10.8 oz) + 2L (64 oz) clear fluids</td>
<td>Bowel cleansing before colonoscopy in adults: split dosing, 2-day or evening-before (1-day)</td>
<td>&gt; 1% of patients: nausea, headache, and vomiting</td>
</tr>
<tr>
<td>Sodium phosphate tablets</td>
<td>Sodium phosphate</td>
<td>32 tablets + 2L (64 oz) clear fluids</td>
<td>Bowel cleansing before colonoscopy in adults: split dosing, 2-day</td>
<td>&gt; 3% of patients: abdominal bloating, nausea, abdominal pain, and vomiting Note: black box warning noting rare but serious reports of acute phosphate nephropathy</td>
</tr>
<tr>
<td>Magnesium citrate</td>
<td>Magnesium citrate</td>
<td>20–30 oz + 2L (64 oz) water</td>
<td>Constipation (available OTC)</td>
<td>Not available in US prescribing information (not FDA-approved as bowel preparation)</td>
</tr>
<tr>
<td>PEG-3350</td>
<td>PEG-3350</td>
<td>2L (64 oz)</td>
<td>Constipation (available OTC)</td>
<td>Not available in US prescribing information (not FDA-approved as bowel preparation)</td>
</tr>
</tbody>
</table>

[^1]: Most common AEs and cutoff rates provided based on reporting in the US prescribing information for bowel cleansing before colonoscopy indication.

[^AE]: adverse event; FDA, US Food and Drug Administration; OTC, over the counter; PEG, polyethylene glycol.


[^AE]: adverse event; FDA, US Food and Drug Administration; OTC, over the counter; PEG, polyethylene glycol.


[^AE]: adverse event; FDA, US Food and Drug Administration; OTC, over the counter; PEG, polyethylene glycol.

rate in the right colon [115]. In addition, the overall tolerability and safety profiles were similar for the two formulations [115].

In another study, NER1006 was noninferior to sodium picosulfate/magnesium oxide and anhydrous citric acid for overall colon cleansing, ascending colon/cecum cleansing, and lesion detection rates, and both preparations were well tolerated [117]. NER1006 was noninferior to oral sulfate solution for overall cleansing of the bowel and high-quality cleansing of the ascending colon, with comparable lesion detection rates, tolerability, and adherence [116]. Of note, more patients randomly assigned to NER1006 (39.3%) than to oral sulfate solution (42.2%) had reversible shifts in sodium levels from baseline to high (based on laboratory normal ranges at study sites) at visit 2 (day of colonoscopy). However, the increased sodium levels did not persist, and no patients required treatment for electrolyte imbalances [116]. To limit the possibility of hypernatremia and dehydration, it is recommended that patients remain adequately hydrated before, during, and after the consumption of NER1006 [116].

Sodium phosphate tablets are the only bowel preparation agent available in tablet form and are taken with approximately 2L of clear fluids [105]. Although this bowel-cleansing method is efficacious and palatable, it is associated with electrolyte and fluid shifts, and there is risk for acute phosphate nephropathy in susceptible individuals (e.g., increased age, hypovolemia, active colitis, certain concomitant medications) [105, 108].

Oral sulfate solution includes sulfate rather than sodium phosphate to reduce the required bowel preparation volume while addressing concerns related to the fluid and electrolyte shifts associated with sodium phosphate [103, 109]. A prospective, randomized study demonstrated that oral sodium sulfate was as effective as a 4L split-dose PEG and had better patient acceptance, tolerability, and satisfaction [118]. Another prospective, randomized study showed that a greater percentage of patients achieved high-quality cleansing with oral sodium sulfate compared with sodium picosulfate plus magnesium citrate (both administered as split doses; 94.7% vs 85.7%, respectively; P = 0.006). While the frequency of AEs was comparable between bowel preparations, nausea was reported by a significantly greater percentage of patients receiving oral sodium sulfate immediately prior to colonoscopy compared with the rate for sodium picosulfate plus magnesium citrate (44% vs 27%, P = 0.02) [96]. Transient shifts in electrolyte and uric acid levels occurred in some patients with normal baseline levels immediately following split-dose administration of oral sulfate solution: high uric acid (23.5%), low bicarbonate (12.7%), high calcium (10.4%), high bilirubin (8.5%), low sodium (3.1%), and high creatinine (1.9%) [103].

Magnesium citrate is an over-the-counter hyperosmotic bowel preparation product with limited efficacy data [39]. A study of patients in a private-care setting who received bowel preparation the day before colonoscopy indicated that bowel cleansing was significantly better with magnesium citrate (n = 140) compared with an oral sodium phosphate formulation (n = 160; P < 0.001) [119]. Excellent or good cleansing was reported in the right and left colon for 94% and 97%, respectively, of patients who received magnesium citrate versus 73% and 89%, respectively, of patients who received oral sodium phosphate [119]. However, magnesium citrate should not be used in older patients or those with kidney disease, due to the potential for magnesium toxicity, and current guidelines recommend against the routine use of magnesium citrate due to the limited efficacy data and the potential for AEs [39].

Conclusions

Colonoscopy decreases incidence and mortality of CRC. A variety of benchmarks exist to confirm high-quality cleansing in preparation for colonoscopy. Adequate bowel preparation is a central component of these quality benchmarks and can affect colonoscopy completeness, safety, and ADRs. Guidelines support the practice of split-dosing (2-day), with same-day dosing as an option to reduce the runway time (preparation-to-procedure time). High-quality cleansing of the proximal colon is critical for maximizing detection of flat lesions and serrated lesions, which have been implicated in the development of interval CRC. The selection of a bowel preparation agent is based on multiple product-related factors, including efficacy, safety, tolerability, volume, and ease of administration, in conjunction with patient history and preferences. It is critical that healthcare providers and patients recognize the importance of successful bowel preparation and maximize opportunities for its optimization with new developments in colon preparation formulations and administration.

Acknowledgments

Technical editorial and medical writing assistance were provided under the direction of the authors by Mary Beth Moncrief, PhD, and Sophie Bolick, PhD, Synchrony Medical Communications, LLC, West Chester, Pennsylvania, United States. Funding for this support was provided by Salix Pharmaceuticals.

Competing interests

Dr. Sharma is a consultant for Boston Scientific and Olympus Inc. Dr. Burke receives research support from Cancer Prevention Pharmaceuticals and Ferring Pharmaceuticals and serves as a consultant for Aries Pharmaceuticals Inc., Ferring Pharmaceuticals, and Salix Pharmaceuticals. Dr. Johnson serves as a consultant for Aries Pharmaceuticals Inc., WebMD, and HyGleaCare. Dr. Cash is a consultant for Salix Pharmaceuticals.

References


Inadequate bowel preparation can lead to increased patient inconvenience, decreased procedural success, increased polyp detection, and potential complications. Multiple studies have highlighted the importance of optimizing bowel preparation quality to improve diagnostic yield and patient satisfaction. A prospective study of colonscopic cecal intubation in a large safety net health care system found that poor bowel preparation was associated with increased cecal intubation times and a higher rate of incomplete examinations.

A nationwide population-based cohort study evaluated the impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. The study concluded that inadequate bowel preparation significantly increased the risk of missing colorectal polyps and early repeat colonoscopy. A review of the impact of preparation quality on adenoma detection rate further supported these findings, showing that suboptimal bowel preparation led to a decrease in adenoma detection rates.

Furthermore, a prospective study of 10,571 colonoscopies found that enhanced instructions improved the quality of bowel preparation for colonoscopy. The study also highlighted the importance of patient education and communication in optimizing bowel preparation quality.

In conclusion, optimizing bowel preparation quality is critical for improving colorectal cancer screening outcomes. Healthcare providers should prioritize patient education and communication to ensure adequate bowel preparation, thereby improving adenoma detection rates and reducing the need for early repeat colonoscopy.


[90] Harrison NM, Hjekrem MC. Bowel cleansing before colonoscopy: balancing efficacy, safety, cost and patient tolerance. World J Gastrointest Endosc 2012; 4: 8–12


[92] Young LE, Sacks NC, Cyr PL et al. Comparison of claims data on hospitalization rates and repeat procedures in patients receiving a bowel preparation prior to colonoscopy. SAGE Open Med 2017; 5: 1–8


[100] NuyLTELY (polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) [package insert]. Braintree, MA: Braintree Laboratories, Inc.; 2013


[102] Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) [package insert]. Amsterdam, The Netherlands: Norgine B. V.; 2019


[107] MiraLAX (polyethylene glycol 3350, powder for solution, osmotic laxative) [package insert]. Boca Raton, FL: Bayer; 2019


[117] Schreiber S, Baumgart DC, Drenth JPH et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy 2019; 51: 73–84
